Loading...

PainReform Ltd.

PRFX•NASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
$1.38
$-0.00(-0.36%)

PainReform Ltd. (PRFX) Company Profile & Overview

Explore PainReform Ltd.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

PainReform Ltd. (PRFX) Company Profile & Overview

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CEOEhud Geller

Contact Information

https://www.painreform.com
972 3 717 7050
65 Yigal Alon Street, Tel Aviv, 6745442

Company Facts

2 Employees
IPO DateSep 1, 2020
CountryIL
Actively Trading

Frequently Asked Questions

;